JNJ Stock Recent News

Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1

Johnson & Johnson (JNJ, Financial) has finalized the acquisition of V-Wave Ltd, a private medical device company. The pharmaceutical giant agreed to purchase V-Wave for an upfront payment of $600 million.

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.

Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of bladder cancer as the drug did not show superior benefits compared to chemoradiation.

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.

While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stability. This approach, known as risk aversion, is a core concept for investors seeking to minimize portfolio volatility and protect their principal investment.

CHICAGO--(BUSINESS WIRE)--A Circuit Court in Cook County, Ill., has denied a request by Johnson & Johnson (NYSE:JNJ) for a new trial in a mesothelioma lawsuit decided in April, upholding a jury verdict and award of $45 million in the asbestos-related death of a mother of six. Johnson & Johnson raised multiple issues in its motion for a new trial, but in each case, the court either found for the plaintiff or determined that any issue did not substantially prejudice the jury. The decision.

Johnson & Johnson said on Friday it will discontinue its mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue.